Analytical Data
-
基因名
FGFR-4
-
简介
FGFR-4 protein is a tyrosine protein kinase that serves as a cell surface receptor for fibroblast growth factor and controls proliferation, differentiation, migration, lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism, and phosphate and other cellular processes homeostasis. It significantly downregulates CYP7A1 in response to FGF19. FGFR-4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived FGFR-4 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
生物活性
Measured by its ability to inhibit FGF acidic-dependent proliferation of NIH-3T3 mouse fibroblast cells. The ED50 of this effect is 8.197 ng/ml in the presence of 2 ng/mL FGF-acidic, corresponding to a specific activity is 1.219×105 units/mg. Measured by its ability to inhibit FGF acidic-dependent proliferation of NIH-3T3 mouse fibroblast cells. The ED50 of this effect is 8.197 ng/ml in the presence of 2 ng/mL FGF-acidic, corresponding to a specific activity is 1.219×105 units/mg.
-
别名
Fibroblast growth factor receptor 4; FGFR-4; CD334; JTK2; TKF
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
Q03142
-
表达区间
L17-D366
-
氨基酸序列
LSLEASEEMEQEPCLAPILEQQEQVLTVALGQPVRLCCGRTERGRHWYKEGSRLASAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMTVVHNLTLLMDDSLTSISNDEDPKTLSSSSSGHVYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPMPTIHWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENSLGSIRYSYLLDVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHVVINGSSFGADGFPYVQVLKTTDINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDLTWTTATPEARYTD
-
蛋白长度
Extracellular Domain
-
分子量
58-80 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor Receptor 4 (FGFR4) is a member of the fibroblast growth factor receptor family, which plays a crucial role in various biological processes, including cell growth, differentiation, and metabolism. FGFR4 is particularly associated with the progression of several types of cancers, such as hepatocellular carcinoma and prostate cancer, where its overexpression correlates with poor prognosis. Given its significant role in tumorigenesis, FGFR4 has emerged as a potential therapeutic target, driving research into the development of FGFR4-specific inhibitors and therapies. The study of FGFR4 recombinant proteins is vital for understanding its structure-function relationships and interactions with ligands, which can inform the design of selective inhibitors. Furthermore, recombinant FGFR4 proteins facilitate the investigation of downstream signaling pathways, such as the MAPK and PI3K/Akt pathways, that are activated upon FGFR4 engagement. Advances in biotechnological methods have enabled the production of these proteins in various systems, allowing researchers to conduct detailed functional assays and structural analyses. Overall, the characterization of FGFR4 recombinant proteins is a foundational step in developing targeted therapeutics aimed at treating FGFR4-driven malignancies and improving clinical outcomes for patients.
